Combination Therapy of Aspirin and Apyrase for Stroke

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$287,622.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1R43NS071655-01
Award Id:
96484
Agency Tracking Number:
NS071655
Solicitation Year:
n/a
Solicitation Topic Code:
NINDS
Solicitation Number:
n/a
Small Business Information
APT THERAPEUTICS, INC., 4041 Forest Park Avenue, SAINT LOUIS, MO, 63108
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
192266141
Principal Investigator:
RIDONG CHEN
(312) 339-8455
RCHEN@APT-THERAPEUTICS.COM
Business Contact:
RIDONG CHEN
() -
rchen@apt-therapeutics.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. This enzyme strongly inhibits platelet a ctivation and aggregation with modest bleeding risk. We will validate hypothesis that in thromboembolic model of stroke in rats, combination treatment of ASA plus apyrase at acute stage provides more effective protection than ASA or apyrase alone in short term as well as long-term experiments without increasing intracerebral hemorrhage. PUBLIC HEALTH RELEVANCE: We will utilize clinically relevant embolic stroke models in rats to assess neuroprotective effect of aspirin and apyrase treatment.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government